MiR-302a Sensitizes Leukemia Cells to Etoposide by Targeting Rad52

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Nov 2

PMID 29088754

Citations 9

Authors

Xiaoning Liu

Chun Heng

Yuanyuan Li

Liang Yu

Affiliations

Soon will be listed here.

Abstract

miR-302a have been reported to participate in various physiological and pathological processes, however, a role for miR-302a in etoposide (VP-16) resistance of acute myeloid leukemia (AML) has not been reported. In this study, the aberrant expression of miR-302a was analyzed in patients with AML and in the AML HL-60 and U937 cell lines. Overexpression of miR-302a, by targeting the 3'UTR of Rad52, enhanced VP-16 sensitivity in the HL-60 and U937 cell. Accordingly, knockdown of Rad52 sensitized the HL-60 and U937 cells to VP-16-induced apoptosis and proliferation suppression. In addition, miR-302a enhanced the tumor-suppressive effect of VP-16 in a xenograft model of human HL-60 and U937 cell lines. Moreover, miR-302a repressed the AKT/Gsk3β/β-catenin pathway after Rad52 inhibition. Reintroduction of Rad52 reversed miR-302a-induced signaling suppression. The results of the present study demonstrated that miR-302a may be a target for the treatment of AML and a potential indicator of the therapeutic sensitivity of AML to VP-16.

Citing Articles

Novel Insights into RAD52's Structure, Function, and Druggability for Synthetic Lethality and Innovative Anticancer Therapies.

Balboni B, Rinaldi F, Previtali V, Ciamarone A, Girotto S, Cavalli A Cancers (Basel). 2023; 15(6).

PMID: 36980703 PMC: 10046612. DOI: 10.3390/cancers15061817.

Nitroglycerin-induced downregulation of AKT- and ERK1/2-mediated radiation-sensitive 52 expression to enhance pemetrexed-induced cytotoxicity in human lung cancer cells.

Ko J, Chen J, Tseng P, Hsieh J, Chiang C, Liu L Toxicol Res (Camb). 2022; 11(2):299-310.

PMID: 35510237 PMC: 9052323. DOI: 10.1093/toxres/tfac013.

HOXA-AS2 contributes to regulatory T cell proliferation and immune tolerance in glioma through the miR-302a/KDM2A/JAG1 axis.

Zhong C, Tao B, Li X, Xiang W, Peng L, Peng T Cell Death Dis. 2022; 13(2):160.

PMID: 35181676 PMC: 8857186. DOI: 10.1038/s41419-021-04471-4.

Long noncoding RNA SATB1-AS1 contributes to the chemotherapy resistance through the microRNA-580/ 2'-5'-oligoadenylate synthetase 2 axis in acute myeloid leukemia.

Zhou H, Jia X, Yang F, Shi P Bioengineered. 2021; 12(1):6403-6417.

PMID: 34516354 PMC: 8806783. DOI: 10.1080/21655979.2021.1971508.

Proteins from the DNA Damage Response: Regulation, Dysfunction, and Anticancer Strategies.

Molinaro C, Martoriati A, Cailliau K Cancers (Basel). 2021; 13(15).

PMID: 34359720 PMC: 8345162. DOI: 10.3390/cancers13153819.

References

Garzon R, Volinia S, Liu C, Fernandez-Cymering C, Palumbo T, Pichiorri F . MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008; 111(6):3183-9. PMC: 2265455. DOI: 10.1182/blood-2007-07-098749. View

Dohner H, Weisdorf D, Bloomfield C . Acute Myeloid Leukemia. N Engl J Med. 2015; 373(12):1136-52. DOI: 10.1056/NEJMra1406184. View

Jensen P, Sehested M . DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide. Biochem Pharmacol. 1997; 54(7):755-9. DOI: 10.1016/s0006-2952(97)00116-0. View

Hammond S . MicroRNA therapeutics: a new niche for antisense nucleic acids. Trends Mol Med. 2006; 12(3):99-101. DOI: 10.1016/j.molmed.2006.01.004. View

Krutzfeldt J, Poy M, Stoffel M . Strategies to determine the biological function of microRNAs. Nat Genet. 2006; 38 Suppl:S14-9. DOI: 10.1038/ng1799. View

Fareh M, Turchi L, Virolle V, Debruyne D, Almairac F, de-la-Forest Divonne S . The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. Cell Death Differ. 2011; 19(2):232-44. PMC: 3263498. DOI: 10.1038/cdd.2011.89. View

Oom A, Humphries B, Yang C . MicroRNAs: novel players in cancer diagnosis and therapies. Biomed Res Int. 2014; 2014:959461. PMC: 4101974. DOI: 10.1155/2014/959461. View

Liang Z, Ahn J, Guo D, Votaw J, Shim H . MicroRNA-302 replacement therapy sensitizes breast cancer cells to ionizing radiation. Pharm Res. 2012; 30(4):1008-16. PMC: 3594086. DOI: 10.1007/s11095-012-0936-9. View

Meresse P, Dechaux E, Monneret C, Bertounesque E . Etoposide: discovery and medicinal chemistry. Curr Med Chem. 2004; 11(18):2443-66. DOI: 10.2174/0929867043364531. View

10.

Montecucco A, Biamonti G . Cellular response to etoposide treatment. Cancer Lett. 2006; 252(1):9-18. DOI: 10.1016/j.canlet.2006.11.005. View

11.

New J, Sugiyama T, Zaitseva E, Kowalczykowski S . Rad52 protein stimulates DNA strand exchange by Rad51 and replication protein A. Nature. 1998; 391(6665):407-10. DOI: 10.1038/34950. View

12.

Saini S, Arora S, Majid S, Shahryari V, Chen Y, Deng G . Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer. Cancer Prev Res (Phila). 2011; 4(10):1698-709. PMC: 3940389. DOI: 10.1158/1940-6207.CAPR-11-0267. View

13.

Sun W, Shen W, Yang S, Hu F, Li H, Zhu T . miR-223 and miR-142 attenuate hematopoietic cell proliferation, and miR-223 positively regulates miR-142 through LMO2 isoforms and CEBP-β. Cell Res. 2010; 20(10):1158-69. DOI: 10.1038/cr.2010.134. View

14.

Hu H, Gatti R . MicroRNAs: new players in the DNA damage response. J Mol Cell Biol. 2010; 3(3):151-8. PMC: 3104011. DOI: 10.1093/jmcb/mjq042. View

15.

Sayed D, He M, Hong C, Gao S, Rane S, Yang Z . MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. J Biol Chem. 2010; 285(26):20281-90. PMC: 2888441. DOI: 10.1074/jbc.M110.109207. View

16.

Baldwin E, Osheroff N . Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents. 2005; 5(4):363-72. DOI: 10.2174/1568011054222364. View

17.

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

18.

Rosa A, Brivanlou A . A regulatory circuitry comprised of miR-302 and the transcription factors OCT4 and NR2F2 regulates human embryonic stem cell differentiation. EMBO J. 2010; 30(2):237-48. PMC: 3025464. DOI: 10.1038/emboj.2010.319. View

19.

Saultz J, Garzon R . Acute Myeloid Leukemia: A Concise Review. J Clin Med. 2016; 5(3). PMC: 4810104. DOI: 10.3390/jcm5030033. View

20.

Hande K . Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer. 1999; 34(10):1514-21. DOI: 10.1016/s0959-8049(98)00228-7. View